Gene Therapy for Friedreich Ataxia Shows Early Positive Signs

Lexeo Therapeutics has published initial Phase I/II study results for its LX2006 gene therapy for Friedreich ataxia in JAMA Cardiology. The findings suggest the therapy was generally well-tolerated by patients and demonstrated early indications of efficacy, particularly in those with cardiac involvement. This represents an encouraging step in developing treatments for this genetic disorder.